Dr. Laura Esserman

Atossa Therapeutics, Inc. (ATOS)

Equibles does not estimate personal net worth.

Get an email with a short summary when Atossa Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ATOS alerts

About Dr. Laura Esserman

Dr. Laura Esserman has spoken on 1 investor event across 1 company, most recently for Atossa Therapeutics, Inc. on May 19, 2026. Atossa Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Atossa Therapeutics, Inc. includes Steven Quay (CEO), Greg Weaver (CFO), Mark Daniel (CFO and Chief Accounting Officer) and 6 others.

Dr. Laura Esserman on recent calls

“It has a screen where I could just join directly, but it's not working.”

Other, Endoxifen's Role in Breast Cancer | Virtual KOL Event · May 19, 2026

Affiliation history

Atossa Therapeutics, Inc. (ATOS)
Transcript header (unverified)

Current

Company network

Atossa Therapeutics, Inc.

ATOS

Current role

Biotechnology · Healthcare

1 appearance Latest appearance 2026-05-19

View calls and events

Leadership on record at Atossa Therapeutics, Inc.

Steven Quay CEO
Greg Weaver CFO
Mark Daniel CFO, Chief Accounting Officer
Mark J. Daniel CFO
Dr. Tessa Cigler, M.D., M.P.H. Board Member
H. Lawrence Remmel, Esq. Board Member
Jonathan Finn Board Member
Jonathan Finn, CFA Board Member
Shu-Chih Chen Board Member

Recent activity

Investor Update Endoxifen's Role in Breast Cancer | Virtual KOL Event Atossa Therapeutics, Inc. (ATOS)
2026-05-19